Truist reiterates Alnylam stock rating on hypertension drug potential

Truist reiterated its Buy rating and $315 price target on Alnylam, implying roughly 31% upside from the $239.56 share price, following a webcast on hypertension candidate zilebesiran. The Phase 3 ZENITH cardiovascular-outcomes trial remains underway with topline data not expected until 2030; Truist cited infrequent dosing as a potential adherence advantage but questioned whether Phase 2 blood-pressure reductions will produce meaningful cardiovascular benefit. ALNY is down nearly 40% year-to-date despite 95% revenue growth over the past 12 months, while other analysts maintain bullish targets ranging from $318 to $482, with InvestingPro citing a broader $256-$536 range.

Analysis

The relevant valuation question is not whether quarterly blood-pressure lowering is statistically significant, but whether durable angiotensinogen suppression can earn premium reimbursement before outcomes data. A long-duration therapy shifts value toward adherence and physician convenience, but also raises a higher safety bar: any hypotension, renal signal, pregnancy-management issue, or inability to rapidly reverse effect would disproportionately limit use in a primary-care population. That makes this an option-value asset rather than a near-term earnings driver; consensus price targets should not be treated as evidence of de-risking.

For ALNY, the nearer rerating catalysts are execution in its commercial rare-disease franchise and any incremental clinical clarity that narrows the safety/efficacy uncertainty around zilebesiran over the next 6-18 months. The failed cardiovascular endpoint elsewhere in the pipeline increases the market's required proof threshold: investors are likely to discount broad-platform claims until trials demonstrate that biomarker or surrogate improvements translate into outcomes. Competitively, successful infrequent dosing would pressure chronic oral antihypertensive adherence narratives and potentially encroach on device-based hypertension approaches, but those effects are too distant to support a sector pair today.

Contrarian view: the stock's weakness may create an attractive platform-franchise entry only if current revenue growth converts into sustained operating leverage and management avoids using future pipeline optionality to justify elevated R&D intensity indefinitely. Conversely, a safety-related update could compress the hypertension program's embedded value quickly because the addressable population is large but clinically conservative. This webcast is not a standalone catalyst; it is primarily a reminder that the next decisive readout is measured in years, while commercial execution and non-zilebesiran pipeline updates determine the next 1-3 months.

Key Decisions for Investors

• No event-driven position on the webcast itself; treat ALNY as a watch-list long rather than chase analyst-target dispersion. Reassess after the next earnings release for evidence that franchise growth is producing improving operating leverage and unchanged full-year guidance.
• For a 6-18 month horizon, initiate only a scaled ALNY long if valuation remains depressed and management confirms durable commercial momentum without a material increase in R&D or launch-spend guidance; size as a pipeline-risk position, not a hypertension-outcomes trade.
• Use a defined risk trigger: reduce or avoid ALNY if new zilebesiran data identify clinically meaningful renal, hypotension, hepatic, or reversibility concerns, or if management materially lowers commercial guidance. Those developments would impair both hypertension optionality and confidence in platform-wide execution.
• Do not pair ALNY against large-cap cardiometabolic or hypertension-exposed peers yet. The clinical timeline is too long and the article provides no evidence of imminent prescription substitution; revisit only after payer positioning, dosing durability, and safety data establish a credible launch path.